AI assistant
Moleculin Biotech, Inc. — Director's Dealing 2022
Jun 23, 2022
34881_dirs_2022-06-22_f2626750-0fc9-49c0-97aa-8844426d3b6e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moleculin Biotech, Inc. (MBRX)
CIK: 0001659617
Period of Report: 2022-06-20
Reporting Person: PICKER DONALD H (Chief Science Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-06-20 | Stock option (right to buy) | $1.49 | A | 65000 | Acquired | 2032-06-20 | Common stock (65000) | Direct |
| 2022-06-20 | Restricted Stock Units | $ | A | 64667 | Acquired | Common stock (64667) | Direct |
Footnotes
F1: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.
F2: Issued in connection with the reporting person's employment with the Company.
F3: Each restricted stock unit represents a contingent right to receive one shares of Company common stock.
F4: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date.